Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Talcott

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Evidence|September 17, 2002
Prostate cancer: metastaticDror Michaelson, James Talcott, Matthew Smith
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2023
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, James Talcott
Urologic Oncology|March 28, 2008
Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidityJoshua H Petit, Clifford Gluck, W S Kiger, et al.
Future Oncology (London, England)|May 31, 2018
Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostatAjai Chari, Menaka Bhor, Lamis Eldjerou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Clinical Genitourinary Cancer|July 25, 2006
Development of an integrated prostate cancer research information systemWilliam K Oh, Julia Hayes, Carolyn Evan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Evidence|September 17, 2002
Prostate cancer: metastaticDror Michaelson, James Talcott, Matthew Smith
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2023
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, James Talcott
Urologic Oncology|March 28, 2008
Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidityJoshua H Petit, Clifford Gluck, W S Kiger, et al.
Future Oncology (London, England)|May 31, 2018
Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostatAjai Chari, Menaka Bhor, Lamis Eldjerou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2007
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw, Katherine S Virgo, Robert Nam, et al.
Clinical Genitourinary Cancer|July 25, 2006
Development of an integrated prostate cancer research information systemWilliam K Oh, Julia Hayes, Carolyn Evan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
Pageof 1